By: Benzinga
Cantor Fitzgerald Reiterates Buy Rating, $60 PT on Salix Pharmaceuticals Ltd.
In a report published Wednesday, Cantor Fitzgerald reiterated its Buy rating and $60.00 price target on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP ). Cantor Fitzgerald noted, “Management has previously guided to a $150-200M opportunity for this product. We currently model 2013 revenues of $8M, growing to $102M in 2020 (Bloomberg 2013
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here